Health Care [ 4/12 ] | Life Sciences Tools & Services [ 64/75 ]
NASDAQ | Common Stock
Tempus AI, Inc. operates as a healthcare technology company in the United States.
It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests.
The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses.
In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling.
Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application.
It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia.
The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023.
Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 2, 26 | -0.04 Increased by +77.78% | -0.20 Increased by +80.00% |
| Nov 4, 25 | -0.46 Decreased by -84.00% | -0.42 Decreased by -9.52% |
| Aug 8, 25 | -0.22 Increased by +65.08% | -0.25 Increased by +12.00% |
| May 6, 25 | -0.24 Increased by +75.51% | -0.27 Increased by +11.11% |
| Feb 24, 25 | -0.18 | -0.15 Decreased by -17.49% |
| Nov 4, 24 | -0.25 | -0.28 Increased by +10.71% |
| Aug 6, 24 | -0.63 | -1.79 Increased by +64.80% |
| May 29, 24 | -0.98 | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 367.21 M Increased by +82.98% | -54.17 M Decreased by -316.21% | Decreased by -14.75% Decreased by -127.46% |
| Sep 30, 25 | 334.21 M Increased by +84.72% | -79.98 M Decreased by -5.46% | Decreased by -23.93% Increased by +42.91% |
| Jun 30, 25 | 314.63 M Increased by +89.57% | -42.84 M Increased by +92.24% | Decreased by -13.62% Increased by +95.91% |
| Mar 31, 25 | 255.74 M Increased by +75.38% | -68.04 M Decreased by -5.09% | Decreased by -26.60% Increased by +40.08% |
| Dec 31, 24 | 200.68 M Increased by +35.85% | -13.01 M Increased by +74.22% | Decreased by -6.48% Increased by +81.02% |
| Sep 30, 24 | 180.93 M Increased by +32.98% | -75.84 M Decreased by -41.95% | Decreased by -41.92% Decreased by -6.75% |
| Jun 30, 24 | 165.97 M Increased by +25.34% | -552.21 M Decreased by -889.06% | Decreased by -332.72% Decreased by -689.11% |
| Mar 31, 24 | 145.82 M Increased by +26.12% | -64.74 M Decreased by -19.06% | Decreased by -44.40% Increased by +5.59% |